Decision: Favourable
Study Title:
A Phase 2, Open-Label, Multi-Center Study of PDS0101 (R-DOTAP [Versamune®] + HPVmix) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection
NREC Code:
22-NREC-CT-085
Decision:
Favourable
Meeting Date:
27/04/2022
Study Type:
CT application
Principal Investigator:
Dr Cliona Grant
PI Institution:
St. James's Hospital, Dublin
Sponsor:
PDS Biotechnology